Ocean Biomedical’s anti-CHI3L1 antibody demonstrates tumor reduction in EGFR-mutant lung cancer
Oct. 4, 2023
Ocean Biomedical Inc. has demonstrated the effectiveness of its anti-chitinase 3-like-1 (CHI3L1) antibody in suppressing and reversing tumor growth in studies of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) cells.
